Arkadios Wealth Advisors Buys 62 Shares of ICON Public Limited (NASDAQ:ICLR)

Arkadios Wealth Advisors grew its holdings in ICON Public Limited (NASDAQ:ICLR) by 5.0% during the 3rd quarter, Holdings Channel reports. The firm owned 1,293 shares of the medical research company’s stock after purchasing an additional 62 shares during the period. Arkadios Wealth Advisors’ holdings in ICON Public were worth $371,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Liontrust Investment Partners LLP boosted its stake in shares of ICON Public by 19.5% in the 2nd quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock valued at $37,531,000 after purchasing an additional 19,546 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its stake in shares of ICON Public by 15.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock valued at $30,016,000 after purchasing an additional 13,163 shares during the last quarter. Whittier Trust Co. boosted its stake in shares of ICON Public by 12.3% in the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after purchasing an additional 441 shares during the last quarter. Sara Bay Financial bought a new position in shares of ICON Public in the 3rd quarter valued at about $1,143,000. Finally, Motco boosted its stake in shares of ICON Public by 1.5% in the 1st quarter. Motco now owns 3,882 shares of the medical research company’s stock valued at $1,304,000 after purchasing an additional 59 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

NASDAQ ICLR opened at $227.89 on Thursday. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.36. ICON Public Limited has a 12-month low of $220.01 and a 12-month high of $347.72. The company has a market capitalization of $18.80 billion, a PE ratio of 25.41, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22. The firm’s 50 day moving average is $292.12 and its 200-day moving average is $308.52.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the business earned $3.10 earnings per share. ICON Public’s revenue for the quarter was down 1.2% on a year-over-year basis. Equities research analysts anticipate that ICON Public Limited will post 14.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ICLR. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Barclays cut their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. TD Cowen cut their price target on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Finally, Redburn Atlantic started coverage on shares of ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ICON Public has a consensus rating of “Moderate Buy” and a consensus price target of $304.27.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.